Visioneering Technologies, Inc. has presented at the Global Specialty Lens Symposium (GSLS) an update of clinical data of 141 children wearing NaturalVue Multifocal and followed for up to 4 years. Pediatric Myopia, or nearsightedness in children, has undergone explosive growth on a global scale over the past four decades and has become a major worldwide eye health issue. Eye experts generally believe that minimizing the progression of nearsightedness is an important intervention aimed at minimizing life-time risks of blindness and other serious ocular diseases that are related to nearsightedness. Based in part on the clinical research presented at GSLS, Visioneering Technologies, Inc., the makers of NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses, believe their product helps to slow the worsening of myopia, and markets the lenses internationally. The updated data include 141 children (mean age 12.38 ± 3.18 years) being followed for 6 to 48 months (mean 18.5 + 11.6 months). The data were very consistent at each time point, demonstrating approximately 90% decrease (1.00 Diopters, D) in myopic progression, as compared to the rate of progression prior to wearing NaturalVue Multifocal (0.90D (84.1%) at 12-17M; 0.97D (90.7%) at 24-29M; 1.04D (97.2%) at 36-41M; 0.99D (92.5%) at 48M). All timepoints were statistically significantly different from baseline (p < 0.00001). Within a subset of 36 children, axial length was measured. Axial length change from baseline averaged 0.19 + 0.17 mm at 12-17M (p < 0.005, a 0.23mm (55%) reduction as compared to a similar group of children from the same practice). The investigators reported that their patients indicated few or no complaints of visual or comfort issues, that nearly all of the children continued wearing the lenses, and there were no adverse events. The consistency of the decreased myopia progression reported in this data set reflects the potential of NaturalVue Multifocal 1 Day contact lenses in slowing the progression of myopia in children. Continuing this research will further substantiate these findings, and add to the body of knowledge for myopia progression control.